Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
RMC-5552
DRUG
2 trials
Sponsors
Revolution Medicines, Inc.
, Nicholas Butowski
Conditions
Glioblastoma
Recurrent Glioblastoma
Solid Tumors
Phase 1
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Completed
NCT04774952
Revolution Medicines, Inc.
Solid Tumors
Start: 2021-04-07
End: 2024-06-28
Updated: 2025-04-15
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Terminated
NCT05557292
Nicholas Butowski
Glioblastoma, Recurrent Glioblastoma
Start: 2023-04-03
End: 2025-12-31
Updated: 2026-05-06
Related Papers
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.
2025-12-01
Data from The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
2025-12-01
Abstract C020: First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumors
Molecular Cancer Therapeutics
2023-12-01
5 citations
Abstract LB015: Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression
Cancer Research
2023-04-14
1 citations
Abstract LB089: Effective <i>in vivo</i> treatment of endometrial tumor models with coexistent mutant PI3K and PTEN inactivation with a selective bi-steric mTORC1 kinase inhibitor
Cancer Research
2022-06-15
1 citations
Abstract 2662: Bi-steric mTORC1 inhibitor RMC-6272 synergizes with immune checkpoint inhibitors to induce sustained regression of MYC-driven hepatocellular carcinoma
Cancer Research
2022-06-15
The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study.
Journal of Clinical Oncology
2022-06-01
6 citations
Investigating the therapeutic efficacy of a novel mTORC1 inhibitor, RMC‐6272, on liver tumors with b‐catenin activation
The FASEB Journal
2022-05-01